2. Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinyakova L.A., Palagin I.S. Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. Publishing house «Uromedia». Moscow, 2020. 110 p. Russian (Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А., Палагин И.С. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. Издательский дом «Уромедиа». М., 2020. 110 с.).

3. Grette K., Cassity S., Holliday N., Rimawi B.H. Acute pyelonephritis during pregnancy: a systematic review of the aetiology, timing, and reported adverse perinatal risks during pregnancy. J ObstetGynaecol. 2020;40(6):739–748.

4. Wing D.A., Fassett M.J., Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014;210(3):219.e1-6.

5. Sobel J.D. K.D. Urinary tract infections. In: Mandell, Douglas, and Bennett’s Principlesand practice of infectious diseases. Elsevier. Philadelphia, 2010. 957 p.

6. Angelescu K., Nussbaumer-Streit B., Sieben W., Scheibler F., Gartlehner G. Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review. BMC Pregnancy Childbirth. 2016;16(1):336.

7. Gebremedhin K.B., Alemayehu H., Medhin G., Amogne W., Eguale T. Maternal Complications and Adverse Pregnancy Outcomes among Pregnant Women who Acquired Asymptomatic Bacteriuria in Addis Ababa, Ethiopia. Biomed Res Int. 2021;2021:5254997.

8. Koukourikis P., Papaioannou M., Papanikolaou D., Apostolidis A. Urine Biomarkers in the Management of Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. Diagnostics. 2023;13(3):468.

9. Moore A., Doull M., Grad R., Groulx S., Pottie K., Tonelli M., et al. Recommendations on screening for asymptomatic bacteriuria in pregnancy. CMAJ. 2018;190(27):E823–830.

10. Kazemier B.M., Koningstein F.N., Schneeberger C., Ott A., Bossuyt P.M., de Miranda E., et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis. 2015;15(11):1324–1333.

11. Smaill F.M., Vazquez J.C. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2019;2019(11).

12. Nicolle L.E., Gupta K., Bradley S.F., Colgan R., DeMuri G.P., Drekonja D., et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83–110.

13. Zaitsev A.V., Perepanova T.S., Gvozdev M.Yu., Arefyeva O.A. Urinary tract infections. Methodological recommendations No.57 (part 1). M., 2017. p. 26. Зайцев А.В., Перепанова Т.С., Гвоздев М.Ю., Арефьева О.А. Инфекции мочевыводящих путей. Методические рекомендации № 57 (часть 1). М., 2017. с. 26.

14. Degtyareva E.I., Romanova D.G. Urinary tract infections in pregnant women. Medical advice. 2024;1(4):65–72. Russian (Дегтярева Е.И., Романова Д.Г. Инфекции мочевыводящих путей у беременных. Медицинский Совет. 2024;1(4):65–72).

15. Gordovskaya N.B., Korotchaeva Yu.V. Urinary tract infection in pregnant women – focus on asymptomatic bacteriuria. Nephrology. 2020;22(2):81–87. Russian (Гордовская Н.Б., Коротчаева Ю.В. Инфекция мочевыводящих путей у беременных – фокус на бессимптомную бактериурию. Нефрология. 2020;22(2):81–87).

16. Keating G.M. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 2013;73(17):1951–1966.

17. Widmer M., Lopez I., Gülmezoglu A.M., Mignini L., Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. 2015;(11):CD000491.

18. Sultan A., Rizvi M., Khan F., Sami H., Shukla I., Khan H.M. Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann. 2015;7(1):26–30.

19. Cystitis in women. Clinical recommendations of the Russian Federation. 2021; p. 33. Russian (Цистит у женщин. Клинические рекомендации РФ. 2021, с. 33).

20. Kalinderi K., Delkos D., Kalinderis M., Athanasiadis A., Kalogiannidis I. Urinary tract infection during pregnancy: current concepts on a common multifaceted problem. J Obstet Gynaecol. 2018;38(4):448–53.

21. Ny S., Edquist P., Dumpis U., Gröndahl-Yli-Hannuksela K., Hermes J., Kling A.M., et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25–34.

22. Hooton T.M., Vecchio M., Iroz A., Tack I., Dornic Q., Seksek I., et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(11):1509–1515.

23. Johnson C.Y., Rocheleau C.M., Howley M.M., Chiu S.K., Arnold K.E., Ailes E.C. Characteristics of Women with Urinary Tract Infection in Pregnancy. J Womens Health (Larchmt). 2021;30(11):1556–1564.

24. Wallin H.P., Gissler M., Korhonen P.E., Ekblad M.O. New insights into smoking and urinary tract infections during pregnancy using pregnancy-pair design: A population-based register study. Acta ObstetGynecol Scand. 2023;102(1):25–32.

25. Jeon D.H., Jang H.N., Cho H.S., Lee T.W., Bae E., Chang S.H., et al. Incidence, risk factors, and clinical outcomes of acute kidney injury associated with acute pyelonephritis in patients attending a tertiary care referral center. Ren Fail. 2019;41(1):204–210.

26. Howley M.M., Feldkamp M.L., Papadopoulos E.A., Fisher S.C., Arnold K.E., Browne M.L., et al. Maternal genitourinary infections and risk of birth defects in the National Birth Defects Prevention Study. Birth Defects Res. 2018;110(19):1443–1454.

27. Easter S.R., Cantonwine D.E., Zera C.A., Lim K.H., Parry S.I., McElrath T.F. Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia. Am J Obstet Gynecol. 2016;214(3):387.e1-7.

28. Obstetrics. National leadership. Short edition / edited by E.K. Aylamazyan, V.N. Serov, V.E. Radzinsky, G.M. Savelyeva. Moscow: GEOTAR-Media, 2021. 608 p. ISBN 978-5-9704-6104-4.

29. Dikke G.B., Sukhanov A.A., Kukarskaya I.I., et al. Immuno-mediated mechanisms of the inflammatory response in combined infections of the lower genital tract in women. Obstetrics, gynecology and reproduction. 2021;15(3):245–257. Russian (Дикке Г.Б., Суханов А.А., Кукарская И.И., и др. Иммуноопосредованные механизмы воспалительного ответа при сочетанных инфекциях нижнего отдела полового тракта у женщин. Акушерство, гинекология и репродукция. 2021;15(3):245–257).

30. Committee Opinion No. 717: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects. Obstet Gynecol. 2017;130(3):e150–152.

31. Muanda F.T., Sheehy O., Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017;189(17):E625–633.

32. Kogan M.I., Naboka Yu.L., Gudima I.A., Rymashevsky A.N., Vorobyova N.V., Rymashevsky M.A. Microbiota of freshly extracted medium portion of urine in women in the first trimester of pregnancy (pilot study). Reproduction problems. 2023;29(5):73–78. Russian (Коган М.И., Набока Ю.Л., Гудима И.А., Рымашевский А.Н., Воробьева Н.В., Рымашевский М.А. Микробиота свежевыделенной средней порции мочи у женщин вIтриместре беременности (пилотное исследование). Проблемы репродукции. 2023;29(5):73–78).

33. Muanda F.T., Sheehy O., Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017;83(11):2557–2571.

34. Bookstaver P.B., Bland C.M., Griffin B., Stover K.R., Eiland L.S., McLaughlin M. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(11):1052–1062.

35. Rac H., Gould A.P., Eiland L.S., Griffin B., McLaughlin M., Stover K.R., et al. Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. Ann Pharmacother. 2019;53(6):639–651.

36. Nguyen H.T., Pandolfini C., Chiodini P., Bonati M. Tuberculosis care for pregnant women: a systematic review. BMC Infect Dis. 2014;14:617.

37. Matok I., Gorodischer R., Koren G., Landau D., Wiznitzer A., Levy A. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Br J Clin Pharmacol. 2009;68(6):956–962.

38. Mølgaard-Nielsen D., Hviid A. Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort study. Pharmacoepidemiol Drug Saf. 2012;21(3):246–253.

39. Andersen J.T., Petersen M., Jimenez-Solem E., Rasmussen J.N., Andersen N.L., Afzal S., et al. Trimethoprim Use prior to Pregnancy and the Risk of Congenital Malformation: A Register-Based Nationwide Cohort Study. Obstet Gynecol Int. 2013;2013:364526.

40. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Eidelstein M.V., Perepanova T.S., Kozlov R.S. Antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: results of the multicenter study «Darmis-2018». Clinical microbiology and antimicrobial chemotherapy. 2019;21(2):134–146. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «Дармис-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134–146).

41. Khusnutdinova T.A., Shipitsyna E.V., Krysanova A.A., Savicheva A.M., Kapustin R.V. Antibiotic resistance of pathogens of community-acquired urinary tract infections in pregnant women with diabetes mellitus. Journal of Obstetrics and Women’s Diseases. 2023;72(1):53–62. Russian (Хуснутдинова Т.А., Шипицына Е.В., Крысанова А.А., Савичева А.М., Капустин Р.В. Антибиотикорезистентность возбудителей внебольничных инфекций мочевыводящих путей у беременных женщин с сахарным диабетом. Журнал акушерства и женских болезней. 2023;72(1):53–62).

42. Ajmal M., Zamir A., Rehman A.U., Imran I., Saeed H., Majeed A., et al. Clinical pharmacokinetics of cefixime: a systematic review. Xenobiotica. 2023;53(3):149–162.

43. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Eidelstein M.V., Perepanova T.S., Kozlov R.S. The state of antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: the results of the multicenter international study «Darmis-2018». Urologiia. 2020; (1): 19–31. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. Состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевыводящих путей в России, Беларуси и Казахстане: результаты многоцентрового международного исследования «Дармис-2018». Урология. 2020; (1): 19–31).

44. Rafalsky V.V. Antibiotic resistance of pathogens of uncomplicated urinary tract infections in the Russian Federation. Bulletin of Urology. 2018;(3):50–56. Russian (Рафальский В.В. Антибиотикорезистентность возбудителей неосложненных инфекций мочевых путей в Российской Федерации. Вестник урологии. 2018;(3):50–56).

45. Galkin V.V., Dovgan E.V., Kozlov S.N., Rafalsky V.V. Cefixime in comparison with ciprofloxacin in acute uncomplicated cystitis: a clinical and economic study. Clinical microbiology and antimicrobial chemotherapy. 2012;14(1):59–66. Russian (Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. Клиническая микробиология и антимикробная химиотерапия. 2012;14(1):59–66).

46. Rafalskiy V, Pushkar D, Yakovlev S, Epstein O, Putilovskiy M, Tarasov S, et al. Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. J Glob Antimicrob Resist. 2020;21:188–94.

47. Al-Tamimi M., Abu-Raideh J., Albalawi H., Shalabi M., Saleh S. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli. Microbial Drug Resistance. 2019;25(8):1132–1141.

48. Cefixime EXPRESS. Instructions for the medical use of the drug. 21.12.2023. Access mode: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7b401e42-15a2-431a-ae6f-76f92ee2a268. Russian (Цефиксим-ЭКСПРЕСС. Инструкция по медицинскому применению лекарственного препарата. 21.12.2023. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7b401e42-15a2-431a-ae6f-76f92ee2a268).

49. Strategy and tactics of rational use of antimicrobial agents in outpatient practice: Eurasian clinical recommendations / edited by S.V. Yakovlev, S.V. Sidorenko, V.V. Rafalsky, T.V. Spichak. M.: Publishing house «Pre100Print», 2016. 144 p. Russian (Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике: Евразийские клинические рекомендации / под ред. С.В. Яковлева, С.В. Сидоренко, В.В. Рафальского, Т.В. Спичак. М.: Издательство «Пре100Принт», 2016. 144 с.).

50. Zyryanov S.K. A study of the comparative kinetics of the dissolution of cefixime preparations. Pharmateca. 2016;10:67. Russian (Зырянов С.К. Исследование сравнительной кинетики растворения препаратов цефиксима. Фарматека. 2016;10:67.

51. Перечень взаимозаменяемых лекарственных препаратов. 2022. https://www.pharmacokinetica.ru/jour/announcement/view/727

51. Mukhina M.A., Leonova M.V. New oral dosage forms of antibiotics. Medical business.2012;1:16–22. Russian (Мухина М.А., Леонова М.В. Новые пероральные лекарственные формы антибиотиков. Лечебное дело.2012;1:16–22).